Loading
A phase 3 trial of Elranatamab, Elotuzumab, Pomalidomide in multiple myeloma, run by Pfizer, now recruiting.
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) is a phase 3 interventional study registered as NCT06152575 by Pfizer, with 492 participants planned, started 2024-02-08 and due to reach its primary completion in 2026-08-30. Interventions recorded: Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Elranatamab, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib.
Shares Elotuzumab, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Elranatamab, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Elotuzumab, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib.
Shares Elotuzumab, Carfilzomib, Pomalidomide, Bortezomib.
Shares Carfilzomib, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.